Welcome to our dedicated page for Marinus Pharmaceuticals news (Ticker: $MRNS), a resource for investors and traders seeking the latest updates and insights on Marinus Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Marinus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Marinus Pharmaceuticals's position in the market.
Marinus Pharmaceuticals reported a 125% growth in Q1 2024 net product revenue to $7.5 million compared to Q1 2023. Full-year 2024 US ZTALMY net product revenue projected between $33 and $35 million. Plans to announce RAISE trial results in summer 2024 and engage with the FDA for potential filing. Implemented cost reduction measures to extend cash runway into late Q1 2025 with $113.3 million in cash, cash equivalents, and short-term investments as of March 31, 2024.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) will have its Chairman and CEO, Dr. Scott Braunstein, participating in a fireside chat at the RBC Capital Markets 2024 Global Healthcare Conference on May 15 at 1:35 p.m. Eastern Time. The event will be accessible through Marinus' website, with a replay available for 90 days.
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) will provide a business update and report its first quarter 2024 financial results on May 8, 2024. The company focuses on developing therapeutics to treat seizure disorders.